نتائج البحث

1

دورية أكاديمية

Final results of DESTINY-CRC01 investigating trastuzumab deruxtecan in patients with HER2-expressing metastatic colorectal cancer

مصطلحات موضوعية: Área de Medicina Clínica y Epidemiología, Trastuzumab deruxtecan (T-DXd), Metastatic colorectal cancer (mCRC), Objective response rate (ORR)

وصف الملف: application/pdf

العلاقة: https://pubmed.ncbi.nlm.nih.gov/37286557Test/; https://hdl.handle.net/10171/67553Test

الإتاحة: https://hdl.handle.net/10171/67553Test

View record in BASE

2

دورية أكاديمية

Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer

المؤلفون: Cortes, J., Kim, S.-B., Chung, W.-P., Im, S.-A., Park, Y.H., Hegg, R., Kim, M.H., Tseng, L.-M., Petry, V., Chung, C.-F., Iwata, H., Hamilton, E., Curigliano, G., Xu, B., Huang, C.-S., Kim, J.H., Chiu, J.W.Y., Pedrini, J.L., Lee, C., Liu, Y., Cathcart, J., Bako, E., Verma, S., Hurvitz, S.A.

المساهمون: 임석아, Im, S.-A.

مصطلحات موضوعية: ANTIBODY-DRUG CONJUGATE, LUNG-DISEASE ILD, DS-8201A, PERTUZUMAB, DOCETAXEL

العلاقة: New England Journal of Medicine, Vol.386 No.12, pp.1142-1154; 158583; https://hdl.handle.net/10371/179230Test; 000928461300009; 2-s2.0-85127402448

الإتاحة: https://doi.org/10.1056/NEJMoa2115022Test
https://hdl.handle.net/10371/179230Test

View record in BASE

3

دورية أكاديمية

236P Subgroup analysis by disease history and prior treatments of patients (pts) with HER2-positive (HER2+) metastatic breast cancer (MBC) from DESTINY-Breast03, a randomized phase III study of trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1)

المؤلفون: Cortés, J., Im, S-A., Iwata, H., Hamilton, E.P., Hurvitz, S.A., Egorov, A., Cathcart, J., Liu, Y., Bako, E., Curigliano, G.

المصدر: Annals of Oncology ; volume 33, page S645-S646 ; ISSN 0923-7534

مصطلحات موضوعية: Oncology, Hematology

الإتاحة: https://doi.org/10.1016/j.annonc.2022.07.275Test
https://api.elsevier.com/content/article/PII:S0923753422021263?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S0923753422021263?httpAccept=text/plainTest

View record in BASE

4

دورية أكاديمية

LBA1 Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (Pts) with HER2+ metastatic breast cancer (mBC): Results of the randomized phase III DESTINY-Breast03 study

المؤلفون: Cortés, J., Kim, S-B., Chung, W-P., Im, S-A., Park, Y.H., Hegg, R., Kim, M.H., Tseng, L-M., Petry, V., Chung, C-F., Iwata, H., Hamilton, E., Curigliano, G., Xu, B., Lee, C., Liu, Y., Cathcart, J., Bako, E., Verma, S., Hurvitz, S.A.

المساهمون: AstraZeneca, Daiichi-Sankyo

المصدر: Annals of Oncology ; volume 32, page S1287-S1288 ; ISSN 0923-7534

مصطلحات موضوعية: Oncology, Hematology

الإتاحة: https://doi.org/10.1016/j.annonc.2021.08.2087Test
https://api.elsevier.com/content/article/PII:S092375342104391X?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S092375342104391X?httpAccept=text/plainTest

View record in BASE

5

دورية أكاديمية

84MO A phase II, multicenter, open-label study of trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-expressing metastatic colorectal cancer (mCRC): DESTINY-CRC01

المؤلفون: Yoshino, T., Siena, S., Di Bartolomeo, M., Raghav, K., Masuishi, T., Loupakis, F., Kawakami, H., Yamaguchi, K., Nishina, T., Fakih, M., Elez, E., Rodriguez, J., Ciardiello, F., Saxena, K., Yamamoto, E., Kobayashi, K., Bako, E., Okuda, Y., Grothey, A.

المصدر: Annals of Oncology ; volume 31, page S1275 ; ISSN 0923-7534

مصطلحات موضوعية: Oncology, Hematology

الإتاحة: https://doi.org/10.1016/j.annonc.2020.10.104Test
https://api.elsevier.com/content/article/PII:S0923753420425955?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S0923753420425955?httpAccept=text/plainTest

View record in BASE

6

دورية أكاديمية

Disturbed spermatogenic signaling in pituitary adenylate cyclase activating polypeptide-deficient mice

المؤلفون: Reglodi, D, Cseh, S, Somoskoi, B, Fulop, B D, Szentleleky, E, Szegeczki, V, Kovacs, A, Varga, A, Kiss, P, Hashimoto, H, Tamas, A, Bardosi, A, Manavalan, S, Bako, E, Zakany, R, Juhasz, T

المصدر: Reproduction ; volume 155, issue 2, page 127-137 ; ISSN 1470-1626 1741-7899

الإتاحة: https://doi.org/10.1530/rep-17-0470Test
https://rep.bioscientifica.com/view/journals/rep/155/2/REP-17-0470.xmlTest
https://rep.bioscientifica.com/downloadpdf/journals/rep/155/2/REP-17-0470.xmlTest

View record in BASE

7

دورية أكاديمية

Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial

المؤلفون: Siena S., Di Bartolomeo M., Raghav K., Masuishi T., Loupakis F., Kawakami H., Yamaguchi K., Nishina T., Fakih M., Elez E., Rodriguez J., Ciardiello F., Komatsu Y., Esaki T., Chung K., Wainberg Z., Sartore-Bianchi A., Saxena K., Yamamoto E., Bako E., Okuda Y., Shahidi J., Grothey A., Yoshino T.

المساهمون: Siena, S., Di Bartolomeo, M., Raghav, K., Masuishi, T., Loupakis, F., Kawakami, H., Yamaguchi, K., Nishina, T., Fakih, M., Elez, E., Rodriguez, J., Ciardiello, F., Komatsu, Y., Esaki, T., Chung, K., Wainberg, Z., Sartore-Bianchi, A., Saxena, K., Yamamoto, E., Bako, E., Okuda, Y., Shahidi, J., Grothey, A., Yoshino, T.

مصطلحات موضوعية: Adult, Aged, Antibodies, Monoclonal, Humanized, Camptothecin, Colorectal Neoplasm, Female, Human, Immunoconjugate, Italy, Japan, Male, Maximum Tolerated Dose, Middle Aged, Neoplasm Metastasi, Receptor, ErbB-2, Spain, Trastuzumab

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/33961795; info:eu-repo/semantics/altIdentifier/wos/WOS:000657432100046; volume:22; issue:6; firstpage:779; lastpage:789; numberofpages:11; journal:THE LANCET ONCOLOGY; http://hdl.handle.net/11591/452991Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85105300772

الإتاحة: https://doi.org/10.1016/S1470-2045Test(21)00086-3
http://hdl.handle.net/11591/452991Test

View record in BASE